Marc Botteman

7.3k total citations · 1 hit paper
212 papers, 5.5k citations indexed

About

Marc Botteman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marc Botteman has authored 212 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 31 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marc Botteman's work include Bone health and treatments (36 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Prostate Cancer Treatment and Research (26 papers). Marc Botteman is often cited by papers focused on Bone health and treatments (36 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Prostate Cancer Treatment and Research (26 papers). Marc Botteman collaborates with scholars based in United States, Switzerland and Germany. Marc Botteman's co-authors include Chris L. Pashos, Alberto Redaelli, Benjamin L. Laskin, Robert Hauser, Jennifer Stephens, John A. Carter, Jennifer Stephens, J. Brandman, James A. Simon and James Spalding and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Marc Botteman

204 papers receiving 5.3k citations

Hit Papers

The health economics of b... 2003 2026 2010 2018 2003 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The health economics of bladder cancer
    2003 669 citations Marc Botteman et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Marc Botteman 1.3k 1.2k 899 711 530 212 5.5k
Chris L. Pashos 2.4k 1.8× 987 0.8× 1.3k 1.4× 506 0.7× 728 1.4× 156 7.6k
Jim Y. Wan 1.2k 0.9× 498 0.4× 747 0.8× 640 0.9× 921 1.7× 214 5.7k
Ambuj Kumar 1.2k 0.9× 1.0k 0.8× 427 0.5× 586 0.8× 685 1.3× 318 4.9k
James A. Kaye 823 0.6× 1.2k 1.0× 937 1.0× 613 0.9× 595 1.1× 169 5.3k
Irene Helenowski 877 0.7× 1.7k 1.4× 967 1.1× 898 1.3× 683 1.3× 232 5.7k
Milada Cvancarova 1.7k 1.3× 1.6k 1.3× 763 0.8× 455 0.6× 1.4k 2.6× 127 5.4k
Jonathan M. Liff 1.3k 1.0× 3.3k 2.7× 1.4k 1.5× 641 0.9× 768 1.4× 89 6.7k
Tomohiro Matsuda 1.5k 1.1× 2.2k 1.8× 1.5k 1.7× 781 1.1× 600 1.1× 140 5.3k
Matt Hayat 1.2k 0.9× 3.3k 2.7× 1.9k 2.1× 1.3k 1.8× 958 1.8× 6 7.9k
Mieke Van Hemelrijck 1.5k 1.1× 2.3k 1.9× 2.4k 2.7× 1.3k 1.8× 834 1.6× 364 7.8k

Countries citing papers authored by Marc Botteman

Since Specialization
Citations

This map shows the geographic impact of Marc Botteman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Botteman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Botteman more than expected).

Fields of papers citing papers by Marc Botteman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Botteman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Botteman. The network helps show where Marc Botteman may publish in the future.

Co-authorship network of co-authors of Marc Botteman

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Botteman. A scholar is included among the top collaborators of Marc Botteman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Botteman. Marc Botteman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simões, Eric A. F., Marc Botteman, & Viktor Chirikov. (2023). Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011–2017. The Journal of Infectious Diseases. 229(4). 1112–1122. 2 indexed citations
2.
Lindstrom, Richard L., John P. Berdahl, Eric D. Donnenfeld, et al.. (2020). Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model. Journal of Medical Economics. 24(1). 410–420. 22 indexed citations
3.
Johnson, Courtney, et al.. (2020). Medical oncology referral and systemic therapy of patients with advanced stage urothelial carcinoma. Journal of Comparative Effectiveness Research. 9(13). 945–957. 1 indexed citations
4.
5.
Shah, Ruchit, et al.. (2019). Treatment Characteristics for Nonmetastatic Castration-Resistant Prostate Cancer in the United States, Europe and Japan. Future Oncology. 15(35). 4069–4081. 9 indexed citations
6.
Waddington‐Cruz, Márcia, Hartmut Schmidt, Marc Botteman, et al.. (2019). Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet Journal of Rare Diseases. 14(1). 42 indexed citations
7.
Botteman, Marc, et al.. (2019). PRO69 PATIENT AND CAREGIVER PREFERENCES FOR CHARACTERISTICS OF TREATMENT IN HEMOPHILIA A: LITERATURE REVIEW AND QUALITATIVE RESEARCH. Value in Health. 22. S348–S348. 1 indexed citations
8.
9.
Wan, Yi, et al.. (2018). Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. SHILAP Revista de lepidopterología. 1 indexed citations
10.
11.
Schmidt, Hartmut, Márcia Waddington‐Cruz, Marc Botteman, et al.. (2016). Global Prevalence Estimates of Transthyretin Familial Amyloid Polyneuropathy (ATTR-FAP): A Systematic Review and Projections. Value in Health. 19(7). A601–A601. 1 indexed citations
12.
Stephens, Sue, Marc Botteman, M. Cifaldi, & Ben A. van Hout. (2015). Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open. 5(6). e006560–e006560. 10 indexed citations
13.
Solem, Caitlyn T., et al.. (2014). Responsiveness Of The Eq-5d Index And Visual Analog Scale To Changes In Lung Function In Patients With Cystic Fibrosis. Value in Health. 17(3). A178–A178. 4 indexed citations
14.
Solem, Caitlyn T., et al.. (2014). Systematic review of the Q-TWiST in oncology. Value in Health. 17(3). A194–A195. 2 indexed citations
15.
Snedecor, Sonya J., Lavanya Sudharshan, J.C. Cappelleri, et al.. (2013). Systematic review and meta-analysis of pharmacological therapies for pain associated with post-herpetic neuralgia. Journal of Pain. 14(4). S11–S11. 2 indexed citations
16.
Joshi, Avani, John A. Carter, Marc Botteman, & Satyin Kaura. (2011). Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clinical Therapeutics. 33(3). 291–304.e8. 12 indexed citations
17.
Snedecor, Sonya J., et al.. (2010). Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.. PubMed. 13(1). 27–35. 14 indexed citations
18.
Stephens, Jennifer, Ashish V. Joshi, Michael Sumner, & Marc Botteman. (2007). Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opinion on Pharmacotherapy. 8(8). 1127–1136. 10 indexed citations
19.
Botteman, Marc, et al.. (2006). Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS). Annals of the Rheumatic Diseases. 65. 207–208. 1 indexed citations
20.
Ramsdell, Joe, et al.. (1999). A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.. PubMed. 5(8). 1007–24. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chris L. Pashos Breakdown of academic impact, for papers by Jim Y. Wan Breakdown of academic impact, for papers by Ambuj Kumar Breakdown of academic impact, for papers by James A. Kaye Breakdown of academic impact, for papers by Irene Helenowski Breakdown of academic impact, for papers by Milada Cvancarova Breakdown of academic impact, for papers by Jonathan M. Liff Breakdown of academic impact, for papers by Tomohiro Matsuda Breakdown of academic impact, for papers by Matt Hayat Breakdown of academic impact, for papers by Mieke Van Hemelrijck
Rankless by CCL
2026